The hemophilia treatment drugs market is experiencing entry of a large number of new drugs in the market. Few of them have already arrived and other long lasting clotting factors and more promising drugs are on their way to get launched in this market. For instance, follow up data from phase I/II study of hemophilia medicine ?Emicizumab? by Roche has demonstrated promising results regarding safety and prophylactic efficiency in people with severe hemophilia A. Another example is of ?Eloctate? for type A and ?Aprolix? for type B hemophilia, respectively. These two newly arrived biogen products are opposed to commonly prescribe course of three infusions per week as they are longer-acting than traditional treatments and require only one to two infusions per week, due to their new mechanism of action. With increasing attention on?prophylactic treatment, the market for hemophilia drugs is estimated to have a positive outlook over the coming years. The?prophylactic treatment?approach prevents spontaneous bleeding episodes, significantly improves the quality of life in terms of physical activities, and maintains the level of clotting factors above a baseline. According to the studies conducted by the US National Library of Medicine determined that the savings on prophylactic treatment be approximately USD 8,312 to USD 17,675 per bleeding episode in a person. Moreover, this line of treatment reduces joint damage and suffering from pain. Several of such long-acting therapeutics are under development and expected to be launched over the next four years. The shift in preference for?prophylactic treatment?due to its advantages will drive this market?s growth over the forecast period. The Americas led the global hemophilia drugs market in 2017 and is expected to continue its dominance until the end of 2023. The Americas have the highest revenue share in the global market with the US contributing to the majority of this revenue. Several countries in the region have introduced health care reforms which are having a positive impact on the market growth. Moreover, healthcare reforms in the US have also helped reduce the cost of pharmaceutical drugs, increased access to healthcare, and improved the overall quality of healthcare. These healthcare reforms are likely to have a positive impact on healthcare insurance and also reduce hospital stay and overall medical expenses, which will boost this market?s growth in the region. The global Hemophilia Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Hemophilia Drugs market based on company, product type, end user and key regions. This report studies the global market size of Hemophilia Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Hemophilia Drugs in these regions. This research report categorizes the global Hemophilia Drugs market by top players/brands, region, type and end user. This report also studies the global Hemophilia Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors. The following manufacturers are covered in this report, with sales, revenue, market share for each company: Baxalta Bayer CSL Behring Pfizer Alnylam Pharmaceuticals BioMarin Catalyst Biosciences Dimension Therapeutics F. Hoffmann-La Roche Grifols Octapharma Sangamo Biosciences Spark Therapeutics Swedish Orphan Biovitrum Market size by Product Hemophilia A Inhibitors Hemophilia B Von Willebrand Disease Market size by End User Recombinant Therapies Plasma-Derived Therapies Market size by Region North America United States Canada Mexico Asia-Pacific China India Japan South Korea Australia Indonesia Singapore Malaysia Philippines Thailand Vietnam Europe Germany France UK Italy Spain Russia Central & South America Brazil Rest of Central & South America Middle East & Africa GCC Countries Turkey Egypt South Africa The study objectives of this report are: To study and analyze the global Hemophilia Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025. To understand the structure of Hemophilia Drugs market by identifying its various subsegments. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks). Focuses on the key global Hemophilia Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development. To project the value and sales volume of Hemophilia Drugs submarkets, with respect to key regions. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market. In this study, the years considered to estimate the market size of Hemophilia Drugs are as follows: History Year: 2014-2018 Base Year: 2018 Estimated Year: 2019 Forecast Year 2019 to 2025 This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Hemophilia Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources. For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents 1 Study Coverage 1.1 Hemophilia Drugs Product 1.2 Market Segments 1.3 Key Manufacturers Covered 1.4 Market by Type 1.4.1 Global Hemophilia Drugs Market Size Growth Rate by Product 1.4.2 Hemophilia A 1.4.3 Inhibitors 1.4.4 Hemophilia B 1.4.5 Von Willebrand Disease 1.5 Market by End User 1.5.1 Global
